Zdravlje AD Leskovac and Sava Health d.o.o. have entered into a strategic partnership for the distribution and promotion of a segment of Zdravlje’s portfolio in the Serbian market.

This partnership is part of Zdravlje’s 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗕𝟮𝗕 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆, which focuses on outlicensing high-value commercial products across both prescription and consumer categories. By expanding these collaborations, Zdravlje complements its established B2B manufacturing operations, enabling a more focused approach to product sourcing and registration while reinforcing its presence across Central and Eastern Europe.

Over the last 2 months, Zdravlje has successfully concluded 𝘁𝘄𝗼 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗼𝘂𝘁𝗹𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 for the former Yugoslavian markets. The partnership with Sava Health is one of these significant agreements, marking a major step toward expanding patient access to high-quality treatments in the region.

With a robust and diverse product pipeline, Zdravlje remains committed to 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀, and 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗺𝗮𝗿𝗸𝗲𝘁 𝗴𝗿𝗼𝘄𝘁𝗵, ensuring continued development and commercialization of new pharmaceutical solutions in the months and years ahead.